ESTNN previews FNCS Chapter 3 Season 1 and highlights some of the top North American Duos. North America is on…

The post Fortnite FNCS Chapter 3 Season 1: NA Duos to Watch For appeared first on Esports News Network | ESTNN.

Here is the BitPinas guide on how to mint NFT, be it art or any other digital item, on OpenSea, the largest NFT platform.

The post How to Mint on OpenSea | NFT Guide Philippines appeared first on BitPinas.

Following a 3-year deal, Singapore-based crypto assets trading platform Bybit has now become the Principal Team Partner for Oracle Red Bull Racing (Read More)

Manchester, UK, Feb 17, 2022 - (ACN Newswire) - GOmetalaunch Utility token, $URGO Token Seed Sale is live now, with 46% of allocated tokens for seed sales already sold in a space of 14 days, with 14 days remaining for seed sale. Early adopters and $URGO Token holders are feeling euphoric about the endless possibilities and utility of the platform.

Join seed sales at https://urgo.gometalaunch.io

GO labs have been up and doing in efforts to deliver way ahead of the scheduled roadmap, as they are proud to announce that the team have been working around the clock to deliver the Launchpad DAPP ahead of schedule.

To that effect, they are proud to unveil the user Interface of their Launchpad, with the following technical updates effected so far.

• Enabled home page of the Web and Mobile DAPP (DEMO Phase)
• Enabled light and Dark mode on the Web and Mobile DAPP (DEMO Phase)
• Enabled the Open Projects section of the DAPP which shows the projects currently incubating on the Launchpad (DEMO Phase)
• Enabled the Upcoming Projects section of the DAPP which shows future projects to be incubated and IDO dates (DEMO Phase)
• Enabled the Closed Projects section of the DAPP which shows concluded incubations and details of funds raised (DEMO Phase)

To have an in depth preview on the work done so far, kindly visit the GOmetalaunch YouTube Channel: https://youtu.be/Q12XRmPQ9WA

Or join the Telegram Community or announcement Channel to interact with community members and view updates: https://t.me/GOmetalaunch

Announcement Channel: https://t.me/GOmetalaunchNewsletters

Users can also join the fast selling Seed Sale of $URGO Tokens to consolidate the effort of the GO Labs Team.

The Technical update above is not final as Further updates will come up as more features of the DAPP will be enabled.

The floor is also open to community members to make inputs and suggestions as regards the features of the Launchpad DAPP

About GOmetalaunch

GOmetalaunch is the first Cross Chain Metaverse IDO Launchpad being built on the Cardano Blockchain. Metalaunch will act as the gateway to the metaverse, offering GO Community members and Token Holders the opportunity to become the earliest and pioneer adopters of the Metaverse through exclusive Metaverse Project launches that will form the building blocks of the future of the Metaverse.

It is important that interested parties seize the opportunity of the seed sales and private sales to get the $URGO tokens at a very cheap and affordable prize, because the public offerings will be quite high at price.

GOmetalaunch Token Sale Details:

• Seed Sale Allocation: 200,000,000 $URGO Tokens
• Seed Sale Price: 1 ADA = 526 $URGO Tokens
• Sales Page: https://urgo.gometalaunch.io

How to Buy $URGO Tokens

• Step 1: Purchase ADA from any cryptocurrency exchange company for example Coinbase or Binance and send them to the Cardano wallet like Yoroi, Daedalus, Adalite, Nami.
• Step 2: Visit the $URGO Token Sale Page and send ADA to the provided wallet Address.
• Step 3: $URGO tokens will be air dropped to the wallet address used in participating in the Sales

Note:
* Ensure to send ADA from only Cardano wallets like Yoroi, Daedalus, or Adalite not from an exchange wallet.
* $URGO Tokens will be air dropped to users wallet within 24hours of sending ADA, GOmetalaunch solicit users patience.
* Users must reach the Minimum ADA required for each sale round to be eligible to get $URGO Token

Join GOmetalaunch Growing Community, To stay updated on the GOmetalaunch Metaverse Project
Join GOmetalaunch Telegram Community: https://t.me/GOmetalaunch
Telegram Newsletters: https://t.me/GOmetalaunchNewsletters
Twitter Community: https://twitter.com/GOmetalaunch
Medium: https://medium.com/@gometalaunch
YouTube Channel: https://www.youtube.com/channel/UCoIR_758r2OSnpBrfcIdNDg

Media Contact
Contact: Harry Jones
Brand: GOmetalaunch
Email: [email protected]
Website: https://GOmetalaunch.io

SOURCE: GOmetalaunch

Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.com

Regulators need to take preemptive measures, bringing the crypto market to obey rules and regulations as risks from the sector could grow quickly, the Financial Stability Board said. (Read More)

The People’s Bank of China (PBOC), the Chinese central bank, has revealed how its central bank digital currency (CBDC) is being used at the Beijing Winter Olympics. A top PBOC official says, “It seems all the foreign users are using hardware wallets.” Digital Yuan’s Latest Trial A top official from the Chinese central bank, the […]

Lord of the Rings DAO seeks to purchase the intellectual property rights to the beloved Tolkien franchise at an expected price of 2 billion USD. Introducing Lord of the Rings Dao,our goal is simple,buy LOTR rights.Medium coming up in a few days where we will detail our plan to take over middle earth I mean […]

The post DAO Wants To Buy Lord Of The Rings Rights appeared first on CryptoCoin.News.

Ethereum capped 2021 on a high with a 399% annual return. This significant run can be linked to the fact that more participants joined the ETH network at a rate of 1.53 million new addresses monthly. (Read More)

HONG KONG, Feb 17, 2022 - (ACN Newswire) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that, on 11 February 2022 (EST local time), an Investigational New Drug application ("IND"), for the Company's First-in-Class (FIC) asthma therapeutic product SM17 (Humanized anti-IL17RB monoclonal antibody for injection) has been submitted and accepted by the U.S. Food and Drug Administration ("FDA"). The Company plans to initiate the First-In-Human study in the U.S. in first quarter of 2022, once IND is approved by FDA.
SM17 is the world's first monoclonal antibodies targeting IL17BR co-developed by SinoMab and LifeArc (a medical research charity based in the United Kingdom). SM17 has a wide range of indications, including indications with large market volumes such as asthma and diseases with high mortality rates such as idiopathic pulmonary fibrosis. Comparing to other products on the market, SM17 enjoys differentiation advantages. With the preclinical data and unique mechanism of action of SM17, Company believes that SM17 potentially has a broader and more beneficial effect on asthma treatment than other approved biologics.

In the global market, the number of asthma patients is gradually increasing and is expected to reach 247.5 million by 2023 and further increase to 267.7 million by 2030. The number of asthma patients in the PRC is increasing at a greater pace than the global rate and is forecasted to reach 25.6 million by 2023 and further increase to 27.8 million by 2030. In terms of market size, the global asthma market is projected to reach US$25.1 billion by 2023 and US$34.6 billion by 2030. However, the asthma market in the PRC is expected to reach RMB36.4 billion by 2023 and RMB65.0 billion by 2030. In terms of treatment options, traditional asthma treatment is based on inhaled corticosteroid, but they are prone to serious adverse effects, especially in adolescents. Drug resistance can also develop if used for a long time. The introduction of SM17 is expected to provide a better treatment option in terms of the balance of efficacy and safety.

Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "following the acceptance of the IND application for SN1011 for the treatment of multiple sclerosis by the NMPA, the acceptance of the SM17 IND application by the FDA fully demonstrates the efficient execution of the Company's new drug R&D program. There is still an unmet medical need for additional effective therapies, particularly for patients who do not respond to current treatments. We are therefore confident in the enormous prospects of SM17's clinical development. Our core products, including SM03, SN1011 and SM17, is making progress on the clinical R&D smoothly, driving the Company moving steadily towards commercialization. In the future, we will accelerate our projects implementation to bring benefits to patients and create value for shareholders through innovation."

About SM17
SM17 is known to be the world's first humanized, IgG4-k monoclonal antibody for new drug development, which targets IL-17RB. And IL-17RB is a type-I single transmembrane glycoprotein belonging to IL-17 receptor family. The binding of SM17 to IL-17RB could suppress Th2 immune responses induced by a category of cytokines called "alarmin", which has shown to be implicated in the pathogenesis of allergic disease and airway viral responses. Alternative approach targeting upstream mediators of the Th2 inflammatory cascade, such as "alarmins", is expected to have a broader effect on airway inflammation and to provide more effective asthma control than currently available therapies, and products with similar mechanism of action as SM17 have been approved by FDA.

About SinoMab BioScience Limited
SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.


Copyright 2022 ACN Newswire. All rights reserved. www.acnnewswire.comSinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases

The latest report suggests cryptocurrency-based crime hit a new all-time high in 2021, with illicit addresses receiving $14 billion in 2021, which amount was doubled to 2020, according to Chainalysis. (Read More)

Famous actor Ryan Reynolds says crypto is “emerging as a huge, huge player.” The Hollywood star added that “companies are doing a good job of bringing it into a sort of safer, more mainstream light.” Ryan Reynolds Sees Crypto as a Huge Player Hollywood actor Ryan Reynolds shared his view on cryptocurrency in an interview […]

ESTNN looks at some of Europe’s best Duos ahead of FNCS Chapter 3 Season 1. The first Fortnite Champion Series…

The post Fortnite FNCS Chapter 3 Season 1: European Duos To Watch For appeared first on Esports News Network | ESTNN.